Higher chemo dose may boost survival in rare leukemia subtype
NCT ID NCT06744504
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing whether a higher dose of the chemotherapy drug cytarabine, given with standard drugs, improves survival for people with acute myeloid leukemia (AML) that has a specific genetic change called RUNX1-RUNX1T1. The study will enroll 300 adults aged 14 to 60. Participants will be randomly assigned to receive either a standard or intermediate dose of cytarabine during their first round of treatment, followed by additional therapy. The main goal is to see if the higher dose leads to longer overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cytarabine combined with daunorubicin, idarubicin, or cyclophosphamide
- What this could lead to
- If successful, this could show that a higher dose of cytarabine during initial treatment improves survival for people with a specific type of AML.
- What could go wrong
- This is a Phase 3 trial, but it focuses on a rare genetic subtype of AML. Higher chemotherapy doses may increase side effects and risks without guaranteeing better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can pressurized oxygen boost cord blood transplants?
- Personalized leukemia vaccine aims to outsmart relapse
- Supercharged donor cells aim to stop leukemia return after transplant